DE60237145D1 - Chinazolinderivate - Google Patents

Chinazolinderivate

Info

Publication number
DE60237145D1
DE60237145D1 DE60237145T DE60237145T DE60237145D1 DE 60237145 D1 DE60237145 D1 DE 60237145D1 DE 60237145 T DE60237145 T DE 60237145T DE 60237145 T DE60237145 T DE 60237145T DE 60237145 D1 DE60237145 D1 DE 60237145D1
Authority
DE
Germany
Prior art keywords
quinazoline derivatives
agent
compound
theprophylaxis
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237145T
Other languages
German (de)
English (en)
Inventor
Yasunori Kitano
Eiji Kawahara
Tsuyoshi Suzuki
Daisuke Abe
Masahiro Nakajou
Naoko Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60237145D1 publication Critical patent/DE60237145D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60237145T 2001-02-21 2002-02-21 Chinazolinderivate Expired - Lifetime DE60237145D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001045827 2001-02-21
JP2001353525 2001-11-19
PCT/JP2002/001575 WO2002066445A1 (en) 2001-02-21 2002-02-21 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
DE60237145D1 true DE60237145D1 (de) 2010-09-09

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237145T Expired - Lifetime DE60237145D1 (de) 2001-02-21 2002-02-21 Chinazolinderivate

Country Status (10)

Country Link
US (2) US7294629B2 (https=)
EP (1) EP1369418B1 (https=)
JP (1) JP4285996B2 (https=)
KR (1) KR100861486B1 (https=)
CN (1) CN1264824C (https=)
AT (1) ATE475652T1 (https=)
CA (1) CA2442742A1 (https=)
DE (1) DE60237145D1 (https=)
TW (1) TWI309647B (https=)
WO (1) WO2002066445A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
ES2305844T3 (es) 2003-09-16 2008-11-01 Astrazeneca Ab Derivados de quinazolina como inhibidores de tirosina cinasa.
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
KR20060100388A (ko) * 2003-09-25 2006-09-20 아스트라제네카 아베 퀴나졸린 유도체
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US20050192314A1 (en) * 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
US20070270589A1 (en) * 2003-11-28 2007-11-22 Mitsubishi Pharma Corporation Quinazoline Derivative and Process for Producing the Same
JP5032851B2 (ja) 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ キナゾリン誘導体
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
CA2577928A1 (en) * 2004-09-01 2006-03-09 Mitsubishi Pharma Corporation Molecular chaperone function regulator
EP1838712B8 (en) 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
KR100910333B1 (ko) 2005-02-23 2009-07-31 시오노기세이야쿠가부시키가이샤 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
MX2007010399A (es) 2005-02-26 2007-09-25 Astrazeneca Ab Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina.
WO2006106721A1 (ja) * 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
CA2644494A1 (en) * 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
BR112013022552B1 (pt) * 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
WO2014177038A1 (en) 2013-04-28 2014-11-06 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
NZ715687A (en) 2013-07-11 2019-04-26 Acea Biosciences Inc Pyrimidine derivatives as kinase inhibitors
KR20180067584A (ko) 2015-10-09 2018-06-20 아세아 테라퓨틱스 인코포레이티드 피롤로피리미딘 키나아제 억제제의 약학적 염, 물리적 형태 및 조성물, 및 이들의 제조 방법
JP7191446B2 (ja) * 2017-01-30 2022-12-19 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
EP4013749B1 (en) * 2019-08-15 2026-03-11 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
HRP20021005A2 (en) * 2000-06-22 2004-02-29 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
US20070270589A1 (en) * 2003-11-28 2007-11-22 Mitsubishi Pharma Corporation Quinazoline Derivative and Process for Producing the Same

Also Published As

Publication number Publication date
WO2002066445A1 (en) 2002-08-29
KR20030086269A (ko) 2003-11-07
TWI309647B (https=) 2009-05-11
US20040116422A1 (en) 2004-06-17
JP4285996B2 (ja) 2009-06-24
US7294629B2 (en) 2007-11-13
CA2442742A1 (en) 2002-08-29
EP1369418A1 (en) 2003-12-10
EP1369418B1 (en) 2010-07-28
KR100861486B1 (ko) 2008-10-02
US20070265260A1 (en) 2007-11-15
JPWO2002066445A1 (ja) 2004-06-17
CN1264824C (zh) 2006-07-19
EP1369418A4 (en) 2005-09-14
ATE475652T1 (de) 2010-08-15
CN1492860A (zh) 2004-04-28

Similar Documents

Publication Publication Date Title
ATE475652T1 (de) Chinazolinderivate
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
ATE223378T1 (de) Prolineamid-derivate
EA200500508A1 (ru) Диариловые эфиры в качестве антагониста опиоидного рецептора
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
ATE450533T1 (de) Carboxamidderivate
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20051263L (no) Ny anvendelse av benzotiazolderivater
DK1465625T3 (da) Opløste topoisomerase-gifte
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
NO20032261D0 (no) Medisinske preparater
SE0102440D0 (sv) New compound
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
ATE390923T1 (de) Topoisomerase-giftmittel
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
SE9900190D0 (sv) New compounds
SE0301371D0 (sv) New Compounds